Hyaluronic Acid Viscosupplementation Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Knee Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis, Ankle Osteoarthritis and Others), By Treatment Type (Single-Injection, Two-Injection, Three-Injection, Five-Injection), By Dosage Form (Solution, Gel) By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centres), and Region Forecast 2020-2031

Hyaluronic Acid Viscosupplementation Market size was valued at US$ 3.4 billion in 2024 and is expected to reach US$ 5.9 billion by 2031, growing at a significant CAGR of 8.1% from 2025-2031. The key drivers are considered to be an increase in the number of people with osteoarthritis, the obese population due to the change in lifestyle, and the geriatric population contributing towards the growth of the global hyaluronic acid viscosupplementation market. The key challenges include lack of safety and efficacy and complex regulatory process because reimbursement policies of different countries are independent of each other there are a considerable number of pipeline drugs waiting for approval.

Demand for non-surgical methods and high lifestyle-related diseases open up a huge market for the global market. Osteoarthritis is treated using a method called viscosupplementation. Because there is no treatment for arthritis, viscosupplementation is used to help the condition better. It is a viscous fluid called hyaluronate that is injected into the body to help support the synovial fluid's lubricating characteristics.

As a result, it lessens the discomfort associated with osteoarthritis of the knee, improves mobility, and provides a more comfortable level of exercise. This is only utilized when other treatment options have been exhausted and failed to help with the management. The market is fueled by major factors such as an increase in the number of individuals suffering from osteoarthritis, which is expected to move the industry forward. The market is expected to grow throughout the projected period as people become more aware of the new treatments available for osteoarthritis management.

Key Developments:

• In May 2016, Anika Therapeutics introduced CINGAL in Canada. This product helps in the treatment of pain in the knee associated with osteoarthritis.
• In March 2019, SEIKAGAKU CORPORATION announced today the launch of HyLink, in Italy. It is a single-injection viscosupplement for the treatment of knee osteoarthritis